Tonix Pharmaceuticals Holding Corp. — 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. This is an annual report, not a standalone fourth-quarter financial report. Financial amounts below are in U.S. dollars; figures are rounded to millions unless stated otherwise.
Business context
Tonix was a clinical-stage pharmaceutical company with no approved products or product revenue. Its principal candidates were TNX-102 SL, a sublingual cyclobenzaprine formulation being developed for fibromyalgia (FM) and post-traumatic stress disorder (PTSD), and TNX-201 for episodic tension-type headache (ETTH). The company also had preclinical alcohol-dependence and biodefense programs. It reported worldwide development and commercialization rights to its candidates.
Financial performance and liquidity
| Metric | 2014 | 2013 |
|---|---|---|
| Revenue and cost of goods sold | $0 | $0 |
| Research and development expense | $18.617 million | $4.650 million |
| General and administrative expense | $9.039 million | $6.238 million |
| Operating loss | $27.656 million | $10.888 million |
| Net loss | $27.616 million | $10.884 million |
| Net loss per share, basic and diluted | $2.77 | $3.37 |
| Cash used in operating activities | $22.840 million | $8.517 million |
With no revenue, operating margins are not meaningful. R&D spending rose about 300%, mainly from TNX-102 SL development, manufacturing and clinical work; G&A rose about 45%, including compensation and professional services. Net loss increased substantially, while loss per share narrowed as weighted-average shares increased.
At year-end, cash was $38.184 million, versus $8.202 million a year earlier. Working capital was approximately $35.7 million; total assets were $39.542 million, total liabilities $3.450 million, and stockholders’ equity $36.092 million. The balance sheet showed no debt at year-end; $280,000 of related-party promissory notes had been repaid during 2014. Financing activities provided $53.217 million, mainly from common-stock offerings and warrant exercises. Investing activities used $392,000.
After year-end, the February 2015 public offering and partial over-allotment generated approximately $29 million in net proceeds. Management stated that available cash was expected to fund operations and planned clinical trials for at least 12 months, while also anticipating materially higher development spending and potentially needing more capital. Outstanding research and development contract commitments were approximately $11.5 million; minimum lease payments under two office leases totaled approximately $1.87 million.
Material changes and development update
- FM study: In the Phase 2b BESTFIT trial, TNX-102 SL did not meet its primary endpoint of change in average daily pain intensity (p=0.172). A 30% pain-responder analysis was statistically significant (34.0% versus 20.6%; p=0.033), as were reported secondary measures of global improvement, FM impact and sleep quality.
- Tolerability: BESTFIT reported transient tongue or mouth numbness in 42% of treated participants versus 1% on placebo, and bitter taste in 8% versus none. No serious adverse events were reported; completion rates were 86% and 83%, respectively.
- FDA and planned trials: In January 2015, the FDA accepted a 30% pain-responder analysis as the primary endpoint for the planned FM Phase 3 trial. The company expected to start a 500-patient trial in Q2 2015 and report topline results in the second half of 2016. A 12-month open-label FM safety study was expected to finish in August 2015.
- Other programs: The 220-patient PTSD Phase 2 AtEase trial began in January 2015, with initial results expected in the first half of 2016. Tonix planned a 200-patient TNX-201 Phase 2 ETTH trial for Q2 2015, with results expected in Q4 2015.
- Financing and dilution: 2014 stock offerings and warrant exercises funded operations. The subsequent February 2015 offering added approximately $29 million net, but increased the share count. At December 31, 2014, 1.746 million warrants and 1.227 million options were outstanding.
Outlook, risks and unusual items
Management expected R&D expense to increase significantly over the following 12–24 months as clinical programs advanced. The company had no product-sales revenue and expected continued operating losses. Its outlook depended on successful trials, regulatory approvals, financing, manufacturing and eventual market acceptance; no assurance of approval or profitability was provided.
- Clinical and regulatory risk: The BESTFIT primary endpoint failure underscores efficacy risk. Later-stage results may differ from earlier findings; trials may be delayed or fail. Tonix had not previously conducted a Phase 3 trial or submitted an NDA. The intended 505(b)(2) pathway for TNX-102 SL could require additional studies or be unavailable; TNX-201 was expected to require a 505(b)(1) NDA.
- Funding and execution: Continued development required substantial capital. Insufficient or unattractively priced financing could force delays, program reductions or relinquishment of rights. The company also relied on outside clinical research organizations and contract manufacturers.
- Commercial and competitive risks: Competition, uncertain reimbursement and pricing, and the absence of sales and marketing infrastructure could limit adoption even if products were approved.
- Intellectual property: Patent applications and trade secrets were central to the business, but protection, validity and enforceability were uncertain.
- Related-party transactions: In 2014, subsidiaries acquired biodefense intellectual property from entities controlled by CEO Seth Lederman for $250,000 cash and 50,000 shares in total. The filing also reports an $8 million intercompany licensing fee associated with foreign subsidiary results; intercompany balances and transactions are eliminated in consolidation.
- Controls and audit: Management and the independent auditor concluded internal control over financial reporting was effective at December 31, 2014. The auditor issued unqualified opinions on the financial statements and internal controls.
Key facts investors should verify
- Actual cash burn, remaining cash runway and funding needs against planned trials and the approximately $11.5 million of R&D contract commitments.
- Whether the FM Phase 3 trial began as planned, its responder endpoint and results, and completion of long-term safety studies.
- PTSD and ETTH trial progress, enrollment, safety findings and reported outcomes versus stated timelines.
- Net proceeds and share issuance from the February 2015 financing, plus subsequent dilution from options and warrants.
- Regulatory acceptability of the 505(b)(2) strategy for TNX-102 SL and the scope of additional studies required for any NDA.
- Terms, valuation and governance oversight of the related-party biodefense acquisitions and intercompany licensing arrangements.